[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"DIGIMED CO., LTD\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":97},{"warningLetters":4,"total":96},[5,34,55,77],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":29,"recipient_name":30,"body_fetched_at":31,"delivery_method":32,"recipient_title":20,"reference_number":20,"action_taken_date":33,"medical_device_id":20,"response_letter_date":20},1661,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2024-01-09T14:20:00Z\">01\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-07T05:00:00Z\">11\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdeymed-diagnostic-sro-671076-11072023\">Deymed Diagnostic s.r.o.\u003C\u002Fa>","&quot;OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality&quot;","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdeymed-diagnostic-sro-671076-08062025\">\u003Ctime datetime=\"2025-08-12T04:00:00Z\">08\u002F12\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kamil Holub\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Deymed Diagnostic s.r.o.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Kudrnacova 533\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hronov\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>54931\u003C\u002Fspan> \u003Cspan>Nachod CZ\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Czechia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@deymed.com\"> info@deymed.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>\"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality\"\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nCMS # 671076\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCC: valsa@deymed.com\u003C\u002Fp>\n\n\u003Cp>November 7, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kamil Holub:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm Deymed Diagnostic s.r.o., located in Hronov, Nachod, Czech Republic on July 24, 2023, through July 27, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures a variety of Class II, non-sterile, products: 1) BrainFeedback Pro and 2) TruScan LT. Your firm also contract manufactures the following Class II, non-sterile, product: 1) DuoMAG NL. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu>&nbsp;(CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received two responses from Mr. Kamil Holub, Chief Executive Officer (CEO) of Deymed Diagnostic s.r.o. dated August 17, 2023, and September 15, 2023, addressing our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain adequate design control procedures to control the design of the device in order to ensure that specified requirements are met, as required by 21 CFR 820.30(a)\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s Design and Development Procedure, Document #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, states that the purpose of this procedure is to describe control of product development from establishing of requirements on product till transfer to production and following product changes. However, your firm has yet to subject the Class II BrainFeedback PRO to the design control process. Your firm has been shipping these units to the United States (U.S.) since 2015.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and concluded that your firm’s response is not adequate. In your responses, you submitted documentation of your corrective action plan and remediation progress to-date. We acknowledge that your firm opened “CAPA2023\u002F04 BrainFeedback Pro USA Design Controls”, revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Design and Development Procedure so that it specifies design inputs and outputs and a design verification and validation plan, completed personnel training on the new procedures and processes and discontinued the sale of the BrainFeedback Pro in the U.S. In your response dated September 15, 2023, your firm indicates that there are several corrective actions in progress, including but not limited to the following: 1) Test the BrainFeedback Pro for electrical safety according to the latest revision of IEC 60601-1, 2) Make a gap analysis for remaining US devices (TruScan Neurofeedback and DuoMag NL), 3) Complete the Design History File (DHF) for BrainFeedback Pro, 4) Delete BrainFeedback Pro proprietary name in FDA Unified Registration and Listing Systems (FURLS) Database and 5) Delete Unique Device Identifier (UDI) 08592566001017 from the Global Unique Device Identification (GUDID) Database. However, as of October 31, 2023, it does not appear that your firm has deleted its entry in the GUDID Database, and it is not clear what your firm intends to do to ensure that BrainFeedback Pro devices that were previously sold in the US are in compliance with the Quality System Regulation. For this reason, your firm’s response is inadequate.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a)\u003C\u002Fp>\n\n\u003Cp>Specifically, under Section 2.4.1 (page 2) of your firm’s Customer Complaints Procedure - Doc #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, a complaint is defined as follows:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Complaint – …written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, usability, safety, or performance of a medical device that has been released from the organization’s control or related to a service that affects the performance of such medical devices, according to ISO 13485.\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>…any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released for distribution, according to FDA 21 CFR Part 820.\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm has received over 180 complaints from your United States customers since 2019 and none of the complaints have been evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report and if the incidences require a failure investigation. For example:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Complaints (2 total) from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cdiv>&nbsp;\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Ctable>\n\t\u003Cthead>\n\t\t\u003Ctr>\n\t\t\t\u003Cth>Customer Complaint #\u003C\u002Fth>\n\t\t\t\u003Cth>Complaint Description\u003C\u002Fth>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Fthead>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Ftd>\n\t\t\t\u003Ctd>sensitive CRPS patient had red mark on skin for a few days\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Ftd>\n\t\t\t\u003Ctd>failure of liquid cooling unit\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003C\u002Fdiv>\n\n\u003Cp>\u003Cu>Complaints (184 total) from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cdiv>\n\u003Ctable>\n\t\u003Cthead>\n\t\t\u003Ctr>\n\t\t\t\u003Cth>Customer Complaint #\u003C\u002Fth>\n\t\t\t\u003Cth>Complaint Description\u003C\u002Fth>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Fthead>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Ftd>\n\t\t\t\u003Ctd>CP23-017 I have been having problems getting my DeyMed to boot up…\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Ftd>\n\t\t\t\u003Ctd>CP23-013 The client said that a patient felt a mild shock when using the system.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Ftd>\n\t\t\t\u003Ctd>CP22-020 It looks like the device is no longer working. It appears to be a little swollen. Possibly the battery I am assuming.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003C\u002Fdiv>\n\n\u003Cp>\u003Cbr>\nWe reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and determined that the adequacy of your firm’s response cannot be determined at this time. We acknowledge that your firm opened “CAPA2023\u002F04 Customer Complaints”, revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Customer Complaints (filename “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”) and completed personnel training on the new procedures and processes, which includes revised procedures for complaint recording, evaluating, and reporting, including use of the Customer Complaint (CC) form by complaint handling unit members and the documentation of complaints on a complaint register. However, your firm has not completed a retrospective review of all complaints received from your U.S. customers since 2019 and a failure investigation (if required) per the revised procedure provided in your firm’s response. Being that your retrospective review for the cited nonconformance has not been completed, the adequacy of your firm’s response cannot be determined at this time. Please provide documentation of your retrospective review.\u003C\u002Fp>\n\n\u003Cp>3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a). Specifically, your firm has yet to establish procedures for the manufacturing of the various Printed Circuit Board Assembly (PCBA) for the TruScan LT, using the automated pick and place machines (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>The TruScan LT Neurofeedback has a total of \u003Cstrong>(b)(6)\u003C\u002Fstrong> Printed Circuit Boards (PCBs) in each unit. However, your firm has yet to establish procedures or working instructions for the manufacturing of the various PCBs for the TruScan LT using the automated pick and place machines (\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and concluded that your firm’s responses are not adequate. We acknowledge that your firm opened “CAPA2023\u002F05 PCB Manufacturing Process”, revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Document Controls (filename “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”), revised the new printed circuit board work instruction (filename “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”) and completed personnel training on the new procedures and processes. Your firm stated that it plans to complete the installation and qualification of the new automated pick and place machine and a retrospective review of the production processes for other devices (e.g., DuoMag NL and TruScan Neurofeedback Device). However, it is not clear how your firm intends to ensure that all devices in the US market were manufactured to ensure that the device conforms to its specifications. Therefore, your firm’s response is not adequate.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain adequate procedures to ensure that device history records for each batch, lot or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record, as required by 21 CFR 820.184.\u003C\u002Fp>\n\n\u003Cp>Specifically, during this inspection, eleven Device History Records (DHRs) from 2023 (pertaining to the TruScan LT) were selected for review. The following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>None of the DHRs included or referred to the location of the primary identification label and labeling used for each production unit; and\u003C\u002Fli>\n\t\u003Cli>None of the DHRs included or referred to the location of the unique device identifiers (UDIs) used for each production unit.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and concluded that your firm’s responses are not adequate. We acknowledge that your firm opened “CAPA2023\u002F07 DHR to Include Labels and UDIs”, created a new form to record all used device labels into the DHR and revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Document Controls (filename “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”) so that it clearly contains all required elements stated in 21 CFR 820.184 and completed personnel training on the new procedures and processes. However, your firm did not indicate that previous DHRs for US devices would be retrospectively reviewed and updated to ensure the required information is included. Therefore, your firm’s response is not adequate.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 671076 when replying. If you have any questions about the contents of this letter, please contact: Amber Ballard, PhD at Amber.Ballard@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Nina Mezu-Nwaba, PharmD, MPH, MSc\u003Cbr>\nDeputy Director\u003Cbr>\nOHT5: Office of Neurological and Physical\u003Cbr>\nMedicine Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRobert V. Packard (U.S. Agent)\u003Cbr>\nMedical Device Academy Inc.\u003Cbr>\nShrewsbury, VT US 05738\u003Cbr>\nEmail: Rob@13485cert.Com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nKamil Holub\n\nDeymed Diagnostic s.r.o.\n\nKudrnacova 533\n\nHronov\n\n54931 Nachod CZ\n\nCzechia\n\ninfo@deymed.com\n\nIssuing Office:\n\n\"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality\"\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS # 671076\n\nCC: valsa@deymed.com\n\nNovember 7, 2023\n\nDear Mr. Kamil Holub:\n\nDuring an inspection of your firm Deymed Diagnostic s.r.o., located in Hronov, Nachod, Czech Republic on July 24, 2023, through July 27, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures a variety of Class II, non-sterile, products: 1) BrainFeedback Pro and 2) TruScan LT. Your firm also contract manufactures the following Class II, non-sterile, product: 1) DuoMAG NL. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received two responses from Mr. Kamil Holub, Chief Executive Officer (CEO) of Deymed Diagnostic s.r.o. dated August 17, 2023, and September 15, 2023, addressing our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain adequate design control procedures to control the design of the device in order to ensure that specified requirements are met, as required by 21 CFR 820.30(a)\n\nSpecifically, your firm’s Design and Development Procedure, Document #(b)(4), states that the purpose of this procedure is to describe control of product development from establishing of requirements on product till transfer to production and following product changes. However, your firm has yet to subject the Class II BrainFeedback PRO to the design control process. Your firm has been shipping these units to the United States (U.S.) since 2015.\n\nWe reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and concluded that your firm’s response is not adequate. In your responses, you submitted documentation of your corrective action plan and remediation progress to-date. We acknowledge that your firm opened “CAPA2023\u002F04 BrainFeedback Pro USA Design Controls”, revised (b)(4) Design and Development Procedure so that it specifies design inputs and outputs and a design verification and validation plan, completed personnel training on the new procedures and processes and discontinued the sale of the BrainFeedback Pro in the U.S. In your response dated September 15, 2023, your firm indicates that there are several corrective actions in progress, including but not limited to the following: 1) Test the BrainFeedback Pro for electrical safety according to the latest revision of IEC 60601-1, 2) Make a gap analysis for remaining US devices (TruScan Neurofeedback and DuoMag NL), 3) Complete the Design History File (DHF) for BrainFeedback Pro, 4) Delete BrainFeedback Pro proprietary name in FDA Unified Registration and Listing Systems (FURLS) Database and 5) Delete Unique Device Identifier (UDI) 08592566001017 from the Global Unique Device Identification (GUDID) Database. However, as of October 31, 2023, it does not appear that your firm has deleted its entry in the GUDID Database, and it is not clear what your firm intends to do to ensure that BrainFeedback Pro devices that were previously sold in the US are in compliance with the Quality System Regulation. For this reason, your firm’s response is inadequate.\n\n2. Failure to establish and maintain adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a)\n\nSpecifically, under Section 2.4.1 (page 2) of your firm’s Customer Complaints Procedure - Doc #(b)(4), a complaint is defined as follows:\n\nComplaint – …written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, usability, safety, or performance of a medical device that has been released from the organization’s control or related to a service that affects the performance of such medical devices, according to ISO 13485.\n\n…any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released for distribution, according to FDA 21 CFR Part 820.\n\nYour firm has received over 180 complaints from your United States customers since 2019 and none of the complaints have been evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report and if the incidences require a failure investigation. For example:\n\nComplaints (2 total) from (b)(4)\n\nCustomer Complaint #\nComplaint Description\n\n(b)(6)\nsensitive CRPS patient had red mark on skin for a few days\n\n(b)(6)\nfailure of liquid cooling unit\n\nComplaints (184 total) from (b)(4)\n\nCustomer Complaint #\nComplaint Description\n\n(b)(6)\nCP23-017 I have been having problems getting my DeyMed to boot up…\n\n(b)(6)\nCP23-013 The client said that a patient felt a mild shock when using the system.\n\n(b)(6)\nCP22-020 It looks like the device is no longer working. It appears to be a little swollen. Possibly the battery I am assuming.\n\nWe reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and determined that the adequacy of your firm’s response cannot be determined at this time. We acknowledge that your firm opened “CAPA2023\u002F04 Customer Complaints”, revised (b)(4) Customer Complaints (filename “(b)(4)”) and completed personnel training on the new procedures and processes, which includes revised procedures for complaint recording, evaluating, and reporting, including use of the Customer Complaint (CC) form by complaint handling unit members and the documentation of complaints on a complaint register. However, your firm has not completed a retrospective review of all complaints received from your U.S. customers since 2019 and a failure investigation (if required) per the revised procedure provided in your firm’s response. Being that your retrospective review for the cited nonconformance has not been completed, the adequacy of your firm’s response cannot be determined at this time. Please provide documentation of your retrospective review.\n\n3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a). Specifically, your firm has yet to establish procedures for the manufacturing of the various Printed Circuit Board Assembly (PCBA) for the TruScan LT, using the automated pick and place machines ((b)(4) and (b)(4)).\n\nThe TruScan LT Neurofeedback has a total of (b)(6) Printed Circuit Boards (PCBs) in each unit. However, your firm has yet to establish procedures or working instructions for the manufacturing of the various PCBs for the TruScan LT using the automated pick and place machines ((b)(4) and (b)(4)).\n\nWe reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and concluded that your firm’s responses are not adequate. We acknowledge that your firm opened “CAPA2023\u002F05 PCB Manufacturing Process”, revised (b)(4) Document Controls (filename “(b)(4)”), revised the new printed circuit board work instruction (filename “(b)(4)”) and completed personnel training on the new procedures and processes. Your firm stated that it plans to complete the installation and qualification of the new automated pick and place machine and a retrospective review of the production processes for other devices (e.g., DuoMag NL and TruScan Neurofeedback Device). However, it is not clear how your firm intends to ensure that all devices in the US market were manufactured to ensure that the device conforms to its specifications. Therefore, your firm’s response is not adequate.\n\n4. Failure to establish and maintain adequate procedures to ensure that device history records for each batch, lot or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record, as required by 21 CFR 820.184.\n\nSpecifically, during this inspection, eleven Device History Records (DHRs) from 2023 (pertaining to the TruScan LT) were selected for review. The following deficiencies were noted:\n\nNone of the DHRs included or referred to the location of the primary identification label and labeling used for each production unit; and\n\nNone of the DHRs included or referred to the location of the unique device identifiers (UDIs) used for each production unit.\n\nWe reviewed your firm’s responses dated August 17, 2023, and September 15, 2023, and concluded that your firm’s responses are not adequate. We acknowledge that your firm opened “CAPA2023\u002F07 DHR to Include Labels and UDIs”, created a new form to record all used device labels into the DHR and revised (b)(4) Document Controls (filename “(b)(4)”) so that it clearly contains all required elements stated in 21 CFR 820.184 and completed personnel training on the new procedures and processes. However, your firm did not indicate that previous DHRs for US devices would be retrospectively reviewed and updated to ensure the required information is included. Therefore, your firm’s response is not adequate.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 671076 when replying. If you have any questions about the contents of this letter, please contact: Amber Ballard, PhD at Amber.Ballard@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCAPT Nina Mezu-Nwaba, PharmD, MPH, MSc\n\nDeputy Director\n\nOHT5: Office of Neurological and Physical\n\nMedicine Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nRobert V. Packard (U.S. Agent)\n\nMedical Device Academy Inc.\n\nShrewsbury, VT US 05738\n\nEmail: Rob@13485cert.Com","Deymed Diagnostic s.r.o.","deymed-diagnostic-sro-671076-11072023","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdeymed-diagnostic-sro-671076-11072023","2026-10-26T08:08:23.948748+00:00","Warning Letter","Closed Out","2024-01-09","671076","Medical Devices","2025-08-12","\"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality\"","Kamil Holub","2026-08-20T00:23:06.472+00:00","VIA Electronic Mail","2023-11-07",{"id":35,"raw":36,"subject":42,"body_html":43,"body_text":44,"firm_name":45,"letter_id":46,"created_at":19,"fei_number":20,"letter_url":47,"updated_at":48,"action_type":23,"case_status":49,"posted_date":50,"marcs_cms_no":51,"product_type":52,"closeout_date":20,"issuing_office":40,"recipient_name":53,"body_fetched_at":54,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":50,"medical_device_id":20,"response_letter_date":20},1774,[37,38,39,40,41,13,13,13],"\u003Ctime datetime=\"2023-11-02T19:00:00Z\">11\u002F02\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-02T04:00:00Z\">11\u002F02\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F8ohm1-dba-digital-smoke-667303-11022023\">8OHM1 d\u002Fb\u002Fa Digital Smoke\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert Bunn, Brian Bunn, Tonya Bunn, Jon Gooch and Mary Gooch\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owners\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>8OHM1 d\u002Fb\u002Fa Digital Smoke\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3033 Washington Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ogden\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84401\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rob@digitalsmoke.net\"> rob@digitalsmoke.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 2, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Robert Bunn, Mr. Brian Bunn, Ms. Tonya Bunn, Mr. Jon Gooch and Ms. Mary Gooch:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that 8OHM1 d\u002Fb\u002Fa Digital Smoke manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Melon Mint Gum.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003Cbr>\n\u003Cbr>\nPlease note your reference number, ER2300939, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>cc: rob@digitalsmoke.net\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nRobert Bunn, Brian Bunn, Tonya Bunn, Jon Gooch and Mary Gooch\n\nRecipient Title\n\nOwners\n\n8OHM1 d\u002Fb\u002Fa Digital Smoke\n\n3033 Washington Blvd\n\nOgden, UT 84401\n\nUnited States\n\nrob@digitalsmoke.net\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 2, 2023\n\nWARNING LETTER\n\nDear Mr. Robert Bunn, Mr. Brian Bunn, Ms. Tonya Bunn, Mr. Jon Gooch and Ms. Mary Gooch:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that 8OHM1 d\u002Fb\u002Fa Digital Smoke manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Melon Mint Gum.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300939, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\ncc: rob@digitalsmoke.net","8OHM1 d\u002Fb\u002Fa Digital Smoke","8ohm1-dba-digital-smoke-667303-11022023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F8ohm1-dba-digital-smoke-667303-11022023","2026-10-26T08:07:48.191107+00:00","Issued","2023-11-02","667303","Tobacco","Robert Bunn, Brian Bunn, Tonya Bunn, Jon Gooch and Mary Gooch","2026-08-20T00:33:42.383+00:00",{"id":56,"raw":57,"subject":62,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":67,"fei_number":20,"letter_url":68,"updated_at":69,"action_type":23,"case_status":49,"posted_date":70,"marcs_cms_no":71,"product_type":72,"closeout_date":20,"issuing_office":61,"recipient_name":73,"body_fetched_at":74,"delivery_method":75,"recipient_title":20,"reference_number":20,"action_taken_date":76,"medical_device_id":20,"response_letter_date":20},458,[58,59,60,61,62,13,13,13],"\u003Ctime datetime=\"2025-11-25T05:00:00Z\">11\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-17T05:00:00Z\">11\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fswift-digital-group-llc-dba-swadesii-716644-11172025\">Swift Digital Group LLC dba Swadesii \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Neena Chowdary Koganti\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Swift Digital Group LLC dba Swadesii \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10101 Division Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Raleigh\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27603\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@swadesii.com\"> support@swadesii.com \u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:legal@swadesii.com\"> legal@swadesii.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 17, 2025\u003C\u002Fp>\u003Cp>RE: 716644\u003C\u002Fp>\u003Cp>Neena Chowdary Koganti:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fswadesii.com\u002F in September 2025. The FDA has observed that your website offers “Deekshant Thyroid Tablet,” “Hepatina Syrup,” “Dr. Vasishth's Guduchi Tinospora cordifolia ghan Tablets,” “Bico 14 Haslab,” “Singhnad Guggul (A.S.S.),” “Repl Dr. Advice No. 69 Measales (Measles),” “Baryta Carbonicum 200 CH,” “Elaneer Kuzhambu,” “WG-5 Gold Drops,” and “WG-6 Gold Drops” (hereinafter Swadesii products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>Your Swadesii products are especially concerning from a public health perspective. As described below, the labeling of your unapproved “Deekshant Thyroid Tablet,” “Hepatina Syrup,” “Dr. Vasishth's Guduchi Tinospora cordifolia ghan Tablets,” “Bico 14 Haslab,” “Singhnad Guggul (A.S.S.),” “Repl Dr. Advice No. 69 Measales (Measles),” “Baryta Carbonicum 200 CH,” “WG-5 Gold Drops,” and “WG-6 Gold Drops” drug products includes claims to cure, mitigate, treat, or prevent serious and\u002For life-threatening conditions such as measles, cancer, diabetes, stroke, Alzheimer's, and hepatitis, and may cause consumers to forgo, delay, or discontinue medical treatments that have been found safe and effective for such conditions through the FDA review process. In addition, your unapproved “Elaneer Kuzhambu,” drug product is concerning because ophthalmic drug products, which are intended for administration into the eyes, generally pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\u003C\u002Fp>\u003Cp>Based on a review of your website, your Swadesii products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Deekshant Thyroid Tablet\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fambic-deekshant-thyroid-60-tabs:\u003C\u002Fp>\u003Cul>\u003Cli>From the product packaging:\u003Cbr>o In the name of the product – “Thyroid Tablet”\u003Cbr>o “Hypothyroidism\u003Cbr>o Helps in activating thyroid glands”\u003C\u002Fli>\u003Cli>“Description:\u003Cbr>o [N]atural ingredients that are [ ] highly effective in improving the health of the thyroid and avoiding thyroid infections.\u003Cbr>o [E]nhance the immune system and fights seasonal pathogens.\u003Cbr>o It is among the most effective antibacterial . . . help in the efficient functioning of thyroid hormone.\u003Cbr>o With the power of Ambic Deekshant thyroid tablets, you can get your way to a healthier thyroid.\u003Cbr>o This is an effective ayurvedic tablet for thyroid that will help you achieve healthier thyroid hormone levels.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Hepatina Syrup\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fbhargava-hepatina-syrup\u003C\u002Fp>\u003Cul>\u003Cli>From the product packaging:\u003Cbr>o “Liver Tonic”\u003C\u002Fli>\u003Cli>“Description:\u003Cbr>o Bhargava Hepatina Syrup is helpful in the treatment of liver problems such as jaundice and fatty liver.\u003Cbr>o It aids in the improvement of digestive functions and the treatment of hepatocellular jaundice and liver damage as a supportive therapy.\u003Cbr>o It contains Chelidonium majus, a herb that aids in the clearance of toxins from the body and is especially beneficial in the treatment of liver issues.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Dr. Vasishth's Guduchi\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fdr-vasishths-guduchi-30-tabs\u003C\u002Fp>\u003Cul>\u003Cli>“Modulates the immunity – Guduchi has been reported to modulate the abnormal immunity as happens in auto-immunity (where the immune cells attack own cells).\u003C\u002Fli>\u003Cli>It is thus useful in auto-immune disorders, including – Rheumatoid arthritis, psoriasis, SLE, lichen planus, IBD, multiple sclerosis, alopecia areata and type-I diabetes. . . .\u003C\u002Fli>\u003Cli>It is used for the management of liver disorders – Hepatitis, jaundice, abnormal liver enzymes, fatty liver, and early cirrhosis.\u003C\u002Fli>\u003Cli>Useful in acid peptic diseases – Guduchi has been reported to inhibit the excessive production of gastric acid. . . .&nbsp;\u003C\u002Fli>\u003Cli>It is useful in the management of various kidney disorders – Early \u002F reversible kidney failure, nephritis and nephrotic syndrome.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Bico 14 Haslab\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fhaslab-homeopathy-bico-14-biochemic-compound-tablets:\u003C\u002Fp>\u003Cul>\u003Cli>“Description: . . .\u003Cbr>o It helps in all stages of disease and fevers of unknown origin; dry, hard, painful, itchy cough with sore chest.\u003Cbr>o [M]anage measles problems.”\u003C\u002Fli>\u003Cli>“Key Benefits:\u003Cbr>o It may help to reduce sneezing and watery discharge from the nose and eyes with fever\u003Cbr>o [H]elp to boost your immune system\u003Cbr>o [P]revent catarrhal affections\u003Cbr>o It can help to condition dry, hard, painful, itchy cough with sore chest”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Singhnad Guggul (A.S.S.)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fpatanjali-divya-singhnda-guggul-20-gms\u003C\u002Fp>\u003Cul>\u003Cli>“Description:\u003Cbr>o Beneficial in chronic rheumatism (arthritis rimutaid), paralysis stroke, arthritis, etc. . . .\u003Cbr>o This is used for all types of vata diseases. This enhances and stimulates the uterus, regulates menstrual disorders, growth of white blood cells in blood, diuretics, mucilage secretory, worm destroyer etc.”\u003C\u002Fli>\u003Cli>“Benefits:\u003Cbr>o Useful in rheumatoid . . . arthritis”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Repl Dr. Advice No. 69 Measales (Measles)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fdr-advice-no-69-measaless-lp8kj:\u003C\u002Fp>\u003Cul>\u003Cli>From the product packaging:\u003Cbr>o In the name of the product – “measles”\u003C\u002Fli>\u003Cli>“Description:\u003Cbr>o Helps with symptoms associated with inflammation of the mucous membranes.\u003Cbr>o Helps with symptoms like measles, red rash in measles, and measles outbreaks.\u003Cbr>o Helps with burns, Heat, burning, red and shiny swelling of the diseased organs.\u003Cbr>o Helps to get rid of problems like swelling, heat, and redness of the whole body.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Baryta Carbonicum 200 CH\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fsbl-homeopathy-baryta-carbonicum-dilution:\u003C\u002Fp>\u003Cul>\u003Cli>“[R]ecommended for old people when they suffer from paralysis and is used in multiple sclerosis of the brain and spinal cord.\u003C\u002Fli>\u003Cli>The elderly people have senile dementia, a disorder showing deterioration of mental abilities usually associated with getting old.\u003C\u002Fli>\u003Cli>Stroke and Alzheimer's disease are the two most common causes of this deterioration.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Elaneer Kuzhambu\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fvaidyaratnam-elaneer-kuzhambu-z4vxs:\u003C\u002Fp>\u003Cul>\u003Cli>“[U]sed to help in the treatment of eye ailments and balance the Pitta and Vata doshas to promote eye health.\u003C\u002Fli>\u003Cli>This Ayurvedic medicine for eye health helps calm eye irritation and can supplement the treatment of vision problems that are caused by sun, heat and smoke.\u003C\u002Fli>\u003Cli>The Ayurvedic eye drops helps safeguard you from eye infections and is used to help treat problems such as corneal ulcer, glaucoma, pterygium and the early stage of cataract.\u003C\u002Fli>\u003Cli>It is a natural Ayurvedic formulation that can help in the treatment of conjunctivitis and other eye infections and inflammations.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>WG-5 Gold Drops\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fwheezal-homeopathy-wg-5-gold-drops:\u003C\u002Fp>\u003Cul>\u003Cli>From the product packaging:\u003Cbr>o “Anti Stroke\u003Cbr>o Helps to Restore Blood Flow”\u003C\u002Fli>\u003Cli>“Description:\u003Cbr>o Wheezal WG5 Anti Stroke Gold Drop can improve blood circulation and manage circulatory debility.\u003Cbr>o It may also be useful against increased intracranial tension and brain oedema in . . . patients suffering from brain stroke and other brain-related diseases.\u003Cbr>o The drop’s homoeopathic ingredients might also help dissolve blood clots induced by stroke or other related diseases.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>WG-6 Gold Drops\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fwheezal-homeopathy-wg-6-gold-drops:\u003C\u002Fp>\u003Cul>\u003Cli>From the product packaging:\u003Cbr>o “Pancreas Health\u003Cbr>o Supports normal functioning of Pancreas”\u003C\u002Fli>\u003Cli>“Description:\u003Cbr>o [H]elp relieve pancreatic disorders and balance the normal functioning of the pancreas.\u003Cbr>o [E]ase associated symptoms like abdominal pain, diarrhoea, and other commonpancreatic disorders.&nbsp;&nbsp;\u003Cbr>o It may be helpful against a range of pancreatic disorders, including pancreas malfunction, pancreatitis, cystic fibrosis, and pancreatic cancer.”\u003C\u002Fli>\u003Cli>“Key Benefits:\u003Cbr>o Helps balance and restore normal functioning of pancreas\u003Cbr>o [U]seful against cystic fibrosis, pancreatic cancer, and other associated pancreatic diseases\u003Cbr>o [E]ase related symptoms like malnutrition, abdominal pain, oily stools, and other problems”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your Swadesii products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>We recognize that your “Hepatina Syrup,” “Bico 14 Haslab,” “Repl Dr. Advice No. 69 Measales (Measles),” “Baryta Carbonicum 200 CH,” “WG-5 Gold Drops,” and “WG-6 Gold Drops” are labeled as homeopathic drugs. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “716644” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002Fs\u002F\u003Cbr>Brad Pace, J.D.\u003Cbr>Associate Director\u003Cbr>Office of Unapproved and Labeling Compliance\u003Cbr>Signed on behalf of:\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nNeena Chowdary Koganti\n\nSwift Digital Group LLC dba Swadesii\n\n10101 Division Dr\n\nRaleigh, NC 27603\n\nUnited States\n\nsupport@swadesii.com\n\nlegal@swadesii.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 17, 2025\nRE: 716644\nNeena Chowdary Koganti:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fswadesii.com\u002F in September 2025. The FDA has observed that your website offers “Deekshant Thyroid Tablet,” “Hepatina Syrup,” “Dr. Vasishth's Guduchi Tinospora cordifolia ghan Tablets,” “Bico 14 Haslab,” “Singhnad Guggul (A.S.S.),” “Repl Dr. Advice No. 69 Measales (Measles),” “Baryta Carbonicum 200 CH,” “Elaneer Kuzhambu,” “WG-5 Gold Drops,” and “WG-6 Gold Drops” (hereinafter Swadesii products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nYour Swadesii products are especially concerning from a public health perspective. As described below, the labeling of your unapproved “Deekshant Thyroid Tablet,” “Hepatina Syrup,” “Dr. Vasishth's Guduchi Tinospora cordifolia ghan Tablets,” “Bico 14 Haslab,” “Singhnad Guggul (A.S.S.),” “Repl Dr. Advice No. 69 Measales (Measles),” “Baryta Carbonicum 200 CH,” “WG-5 Gold Drops,” and “WG-6 Gold Drops” drug products includes claims to cure, mitigate, treat, or prevent serious and\u002For life-threatening conditions such as measles, cancer, diabetes, stroke, Alzheimer's, and hepatitis, and may cause consumers to forgo, delay, or discontinue medical treatments that have been found safe and effective for such conditions through the FDA review process. In addition, your unapproved “Elaneer Kuzhambu,” drug product is concerning because ophthalmic drug products, which are intended for administration into the eyes, generally pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\nBased on a review of your website, your Swadesii products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nDeekshant Thyroid Tablet\nOn the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fambic-deekshant-thyroid-60-tabs:\nFrom the product packaging:\no In the name of the product – “Thyroid Tablet”\no “Hypothyroidism\no Helps in activating thyroid glands”\n“Description:\no [N]atural ingredients that are [ ] highly effective in improving the health of the thyroid and avoiding thyroid infections.\no [E]nhance the immune system and fights seasonal pathogens.\no It is among the most effective antibacterial . . . help in the efficient functioning of thyroid hormone.\no With the power of Ambic Deekshant thyroid tablets, you can get your way to a healthier thyroid.\no This is an effective ayurvedic tablet for thyroid that will help you achieve healthier thyroid hormone levels.”\nHepatina Syrup\nOn the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fbhargava-hepatina-syrup\nFrom the product packaging:\no “Liver Tonic”\n“Description:\no Bhargava Hepatina Syrup is helpful in the treatment of liver problems such as jaundice and fatty liver.\no It aids in the improvement of digestive functions and the treatment of hepatocellular jaundice and liver damage as a supportive therapy.\no It contains Chelidonium majus, a herb that aids in the clearance of toxins from the body and is especially beneficial in the treatment of liver issues.”\nDr. Vasishth's Guduchi\nOn the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fdr-vasishths-guduchi-30-tabs\n“Modulates the immunity – Guduchi has been reported to modulate the abnormal immunity as happens in auto-immunity (where the immune cells attack own cells).\nIt is thus useful in auto-immune disorders, including – Rheumatoid arthritis, psoriasis, SLE, lichen planus, IBD, multiple sclerosis, alopecia areata and type-I diabetes. . . .\nIt is used for the management of liver disorders – Hepatitis, jaundice, abnormal liver enzymes, fatty liver, and early cirrhosis.\nUseful in acid peptic diseases – Guduchi has been reported to inhibit the excessive production of gastric acid. . . .\nIt is useful in the management of various kidney disorders – Early \u002F reversible kidney failure, nephritis and nephrotic syndrome.”\nBico 14 Haslab\nOn the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fhaslab-homeopathy-bico-14-biochemic-compound-tablets:\n“Description: . . .\no It helps in all stages of disease and fevers of unknown origin; dry, hard, painful, itchy cough with sore chest.\no [M]anage measles problems.”\n“Key Benefits:\no It may help to reduce sneezing and watery discharge from the nose and eyes with fever\no [H]elp to boost your immune system\no [P]revent catarrhal affections\no It can help to condition dry, hard, painful, itchy cough with sore chest”\nSinghnad Guggul (A.S.S.)\nOn the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fpatanjali-divya-singhnda-guggul-20-gms\n“Description:\no Beneficial in chronic rheumatism (arthritis rimutaid), paralysis stroke, arthritis, etc. . . .\no This is used for all types of vata diseases. This enhances and stimulates the uterus, regulates menstrual disorders, growth of white blood cells in blood, diuretics, mucilage secretory, worm destroyer etc.”\n“Benefits:\no Useful in rheumatoid . . . arthritis”\nRepl Dr. Advice No. 69 Measales (Measles)\nOn the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fdr-advice-no-69-measaless-lp8kj:\nFrom the product packaging:\no In the name of the product – “measles”\n“Description:\no Helps with symptoms associated with inflammation of the mucous membranes.\no Helps with symptoms like measles, red rash in measles, and measles outbreaks.\no Helps with burns, Heat, burning, red and shiny swelling of the diseased organs.\no Helps to get rid of problems like swelling, heat, and redness of the whole body.”\nBaryta Carbonicum 200 CH\nOn the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fsbl-homeopathy-baryta-carbonicum-dilution:\n“[R]ecommended for old people when they suffer from paralysis and is used in multiple sclerosis of the brain and spinal cord.\nThe elderly people have senile dementia, a disorder showing deterioration of mental abilities usually associated with getting old.\nStroke and Alzheimer's disease are the two most common causes of this deterioration.”\nElaneer Kuzhambu\nOn the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fvaidyaratnam-elaneer-kuzhambu-z4vxs:\n“[U]sed to help in the treatment of eye ailments and balance the Pitta and Vata doshas to promote eye health.\nThis Ayurvedic medicine for eye health helps calm eye irritation and can supplement the treatment of vision problems that are caused by sun, heat and smoke.\nThe Ayurvedic eye drops helps safeguard you from eye infections and is used to help treat problems such as corneal ulcer, glaucoma, pterygium and the early stage of cataract.\nIt is a natural Ayurvedic formulation that can help in the treatment of conjunctivitis and other eye infections and inflammations.”\nWG-5 Gold Drops\nOn the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fwheezal-homeopathy-wg-5-gold-drops:\nFrom the product packaging:\no “Anti Stroke\no Helps to Restore Blood Flow”\n“Description:\no Wheezal WG5 Anti Stroke Gold Drop can improve blood circulation and manage circulatory debility.\no It may also be useful against increased intracranial tension and brain oedema in . . . patients suffering from brain stroke and other brain-related diseases.\no The drop’s homoeopathic ingredients might also help dissolve blood clots induced by stroke or other related diseases.”\nWG-6 Gold Drops\nOn the webpage https:\u002F\u002Fswadesii.com\u002Fproducts\u002Fwheezal-homeopathy-wg-6-gold-drops:\nFrom the product packaging:\no “Pancreas Health\no Supports normal functioning of Pancreas”\n“Description:\no [H]elp relieve pancreatic disorders and balance the normal functioning of the pancreas.\no [E]ase associated symptoms like abdominal pain, diarrhoea, and other commonpancreatic disorders.\no It may be helpful against a range of pancreatic disorders, including pancreas malfunction, pancreatitis, cystic fibrosis, and pancreatic cancer.”\n“Key Benefits:\no Helps balance and restore normal functioning of pancreas\no [U]seful against cystic fibrosis, pancreatic cancer, and other associated pancreatic diseases\no [E]ase related symptoms like malnutrition, abdominal pain, oily stools, and other problems”\nYour Swadesii products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nWe recognize that your “Hepatina Syrup,” “Bico 14 Haslab,” “Repl Dr. Advice No. 69 Measales (Measles),” “Baryta Carbonicum 200 CH,” “WG-5 Gold Drops,” and “WG-6 Gold Drops” are labeled as homeopathic drugs. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “716644” in the subject line of the email.\nSincerely,\n\u002Fs\u002F\nBrad Pace, J.D.\nAssociate Director\nOffice of Unapproved and Labeling Compliance\nSigned on behalf of:\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Swift Digital Group LLC dba Swadesii","swift-digital-group-llc-dba-swadesii-716644-11172025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fswift-digital-group-llc-dba-swadesii-716644-11172025","2026-10-26T08:10:08.768063+00:00","2025-11-25","716644","Drugs","Neena Chowdary Koganti","2026-08-19T14:12:44.952+00:00","Via Email","2025-11-17",{"id":78,"raw":79,"subject":84,"body_html":85,"body_text":86,"firm_name":87,"letter_id":88,"created_at":67,"fei_number":20,"letter_url":89,"updated_at":90,"action_type":23,"case_status":49,"posted_date":91,"marcs_cms_no":92,"product_type":27,"closeout_date":20,"issuing_office":83,"recipient_name":93,"body_fetched_at":94,"delivery_method":32,"recipient_title":20,"reference_number":20,"action_taken_date":95,"medical_device_id":20,"response_letter_date":20},31,[80,81,82,83,84,13,13,13],"\u003Ctime datetime=\"2026-07-14T04:00:00Z\">07\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-12T04:00:00Z\">06\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnihon-kohden-digital-health-solutions-llc-727803-06122026\">Nihon Kohden Digital Health Solutions, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Harsh Dharwad\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nihon Kohden Digital Health Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14 Bunsen\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #727803\u003C\u002Fp>\u003Cp>June 12, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Dharwad:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Irvine, CA from February 23, 2026 through February 24, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Next Generation NetKonnect software device, which is a Patient Physiological Monitor device with Arrhythmia detector and alarm (including ST-segment measurement and alarm). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your Next Generation NetKonnect (NGNK) software device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)(1)(i)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and respond as appropriate.\u003C\u002Fp>\u003Cp>Specifically, your firm’s Next Generation NetKonnect software devices are class II devices regulated under 21 CFR 870.1025 - Arrhythmia detector and alarm (including ST-segment measurement and alarm). Your device was most recently cleared as K220989 on July 29, 2022. On October 22, 2022, you implemented a software change to the device which included the ability to enable a Silence Alarms function. This introduced a device functionality that was not included in the originally cleared device. You completed a Regulatory Assessment for the modification in which you determined it would not significantly affect the safety and efficacy of the device, and that a Letter-to-File was appropriate. At decision point B2 of the assessment, “Is it a control mechanism, operating principles, or energy type change?” you selected “No.” You did not submit a premarket notification for this modification.\u003C\u002Fp>\u003Cp>However, we disagree with this assessment because adding the Silence Alarms function is a change to a control mechanism of the device and we believe that “Yes” should have been selected, leading to “New 510(k).” The addition of a Silence Alarms function is a change to a control mechanism because it modifies the manner in which the user controls the device, which could result in the alarms not operating as the user intends. This change may result in missed alarms for life-threatening conditions that require immediate attention, leading to patient harm such as serious injury and\u002For death. As such, the modification of the device is a change or modification in the device that could significantly affect its safety or effectiveness and requires submission of a 510(k) under 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>Additionally, the evidence indicates that you are distributing the NGNK software device with an unauthorized intended use that is different from that cleared under K220989. Namely, the labeling of your device indicates that the NGNK device is now intended to have “device-agnostic compatibility.” During the inspection, your firm’s management explained that “device-agnostic” describes NGNK’s ability to 1) run on any brand of commercial off-the-shelf computer and 2) support input from non-Nihon Kohden devices. However, your device was cleared under K220989 to support inputs from only other Nihon Kohden devices, and not from any device from other manufacturers. Therefore, “device-agnostic compatibility” is beyond the scope of the intended use that was cleared for the Next Generation NetKonnect. This change may introduce patient risks because of the use of additional input devices that have not been validated for compatibility with the NGNK software. Inadequate interoperability can result in incorrect vital sign measurements or loss of expected monitoring, which may result in delay of diagnosis or misdiagnosis. This is a major change or modification in the intended use of the device and requires submission of a 510(k) under 21 CFR 807.81(a)(3)(ii).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727803” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CDR Cesar A. Perez, PhD, USPHS\u003Cbr>Acting Deputy Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Mr. Arthur E. Webb, Director of Software Quality and Regulatory Affairs, art_webb@nihonkohden.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nHarsh Dharwad\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nNihon Kohden Digital Health Solutions, LLC\n\n14 Bunsen\n\nIrvine, CA 92618\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #727803\nJune 12, 2026\nDear Mr. Dharwad:\nDuring an inspection of your firm located in Irvine, CA from February 23, 2026 through February 24, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Next Generation NetKonnect software device, which is a Patient Physiological Monitor device with Arrhythmia detector and alarm (including ST-segment measurement and alarm). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nUnapproved Device Violation(s)\nOur inspection revealed that your Next Generation NetKonnect (NGNK) software device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)(1)(i)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and respond as appropriate.\nSpecifically, your firm’s Next Generation NetKonnect software devices are class II devices regulated under 21 CFR 870.1025 - Arrhythmia detector and alarm (including ST-segment measurement and alarm). Your device was most recently cleared as K220989 on July 29, 2022. On October 22, 2022, you implemented a software change to the device which included the ability to enable a Silence Alarms function. This introduced a device functionality that was not included in the originally cleared device. You completed a Regulatory Assessment for the modification in which you determined it would not significantly affect the safety and efficacy of the device, and that a Letter-to-File was appropriate. At decision point B2 of the assessment, “Is it a control mechanism, operating principles, or energy type change?” you selected “No.” You did not submit a premarket notification for this modification.\nHowever, we disagree with this assessment because adding the Silence Alarms function is a change to a control mechanism of the device and we believe that “Yes” should have been selected, leading to “New 510(k).” The addition of a Silence Alarms function is a change to a control mechanism because it modifies the manner in which the user controls the device, which could result in the alarms not operating as the user intends. This change may result in missed alarms for life-threatening conditions that require immediate attention, leading to patient harm such as serious injury and\u002For death. As such, the modification of the device is a change or modification in the device that could significantly affect its safety or effectiveness and requires submission of a 510(k) under 21 CFR 807.81(a)(3)(i).\nAdditionally, the evidence indicates that you are distributing the NGNK software device with an unauthorized intended use that is different from that cleared under K220989. Namely, the labeling of your device indicates that the NGNK device is now intended to have “device-agnostic compatibility.” During the inspection, your firm’s management explained that “device-agnostic” describes NGNK’s ability to 1) run on any brand of commercial off-the-shelf computer and 2) support input from non-Nihon Kohden devices. However, your device was cleared under K220989 to support inputs from only other Nihon Kohden devices, and not from any device from other manufacturers. Therefore, “device-agnostic compatibility” is beyond the scope of the intended use that was cleared for the Next Generation NetKonnect. This change may introduce patient risks because of the use of additional input devices that have not been validated for compatibility with the NGNK software. Inadequate interoperability can result in incorrect vital sign measurements or loss of expected monitoring, which may result in delay of diagnosis or misdiagnosis. This is a major change or modification in the intended use of the device and requires submission of a 510(k) under 21 CFR 807.81(a)(3)(ii).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727803” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nCDR Cesar A. Perez, PhD, USPHS\nActing Deputy Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Mr. Arthur E. Webb, Director of Software Quality and Regulatory Affairs, art_webb@nihonkohden.com","Nihon Kohden Digital Health Solutions, LLC","nihon-kohden-digital-health-solutions-llc-727803-06122026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnihon-kohden-digital-health-solutions-llc-727803-06122026","2026-10-26T08:09:33.79279+00:00","2026-07-14","727803","Harsh Dharwad","2026-08-19T04:30:04.336+00:00","2026-06-12",4,{"510k":98,"classification":99,"enforcement":100,"event":101,"event_backfill":102,"pma":103,"warning_letter":104},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]